NCT05565014 2022-10-04Safety and Efficacy Study of Virus Activated Killer Immune Cells (VAK) for Malignant Pleural and Peritoneal EffusionHubei Cancer HospitalPhase EARLY_PHASE1 Unknown90 enrolled